Angiotensin II antagonism and the heart: Valsartan in left ventricular hypertrophy

Journal of Cardiovascular Pharmacology

Volumn 33, Issue SUPPL. 1, 1999, Pages

  Thürmann, Petra A ^a,b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b HELIOS KLINIKUM WUPPERTAL   (Germany)

Author keywords

Angiotensin II antagonism; Antihypertensive therapy; Essential hypertension; Left ventricular hypertrophy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ATENOLOL; HYDROCHLOROTHIAZIDE; RECEPTOR SUBTYPE; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 0032934965     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199900001-00007     Document Type: Conference Paper

References (27)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-6.
2. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1996;78:197-202.
3. Dahlöf B. Factors involved in the pathogenesis and consequences of hypertensive hypertrophy - a review. Drugs 1988;35(Suppl 5): 6-26.
4. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circulation 1993;73:413-23.
5. MacMahon S, Collins G, Rautaharju P, et al. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the multiple risk factor intervention trial (MRFIT). Am J Cardiol 1989;63:202-10.
6. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091-5.
7. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
8. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6:85-90.
9. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265: 22348-57.
10. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.
11. Dahlöf B. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. J Hum Hypertens 1995;9(Suppl 5):S37-44.
12. 1-receptor subtype. Br J Pharmacol 1993;110:761-71.
13. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996;60:341-6.
14. 1,-receptor blockade. Cardiovasc Res 1996;31:758-68.
15. Nicoletti A, Heudes D, Hinglais N, et al. Left ventricular fibrosis in renovascular rats. Effect of losartan and spironolactone. Hypertension 1995;26:101-11.
16. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
17. Himmelmann A, Svensson A, Bergbrant A, Hansson L. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. J Hum Hypertens 1996;10:729-34.
18. Agabiti-Rosei E, Ambrosioni E, Dal Palu C, Muiesan ML, Zanchetti A. ACE inhibitor ramipril is more effective than the β-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (Ramipril Cardioprotective Evaluation) study. J Hypertens 1995;13:1325-34.
19. Brink M, de Gasparo M, Rogg H, Schmid A, Stulz P, Bullock G. Localization of the angiotensin II receptor subtypes in the human atrium. J Mol Cell Cardiol 1996;28:1789-99.
20. 2-receptor subtypes in hypertrophied rat hearts. Am J Physiol 1994;267:H844-52.
21. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996; 93:156-60.
22. Liu Y-H, Yang X-P, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest 1997;99:1926-35.
23. Kojima M, Shiojima I, Yamazaki T, et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994;89:2204-11.
24. Kometani M, Hayashi N, Yamamato S, Nakao K, Inukai T. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. Arznemittelforschung 1997;47(Suppl 1):613-9.
25. Kohya T, Yokoshiki H, Tohse N, et al. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Circ Res 1995;76: 892-9.
26. Thürmann PA. Left ventricular and microvascular hypertrophy in essential hypertension: clinical relevance and prognostic implications. Int J Clin Pharmacol Ther 1997;35:181-7.
27. Ledingham JM, Laverty R. Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist. Clin Exp Pharmacol Physiol 1996; 23:576-8.